CardioCel: 8 years on and still free from calcification
CardioCel® is proving to be one of the biggest game changers in the congenital heart defect repairs and reconstructions space, offering significant long-term benefits to patients. While other tissue patches can calcify up to 18 months post implantation in paediatric patients, the latest follow up data released by Admedus shows no evidence of calcification using […]
August 23rd 2016Find out more
Using the ADAPT engineering process to create durable tissue scaffolds
Admedus is an Australian-based healthcare company leading the world in regenerative medicine and tissue engineering research. Using its proprietary ADAPT® tissue engineering technology, Admedus can transform xenograft (animal) tissue into durable bio-scaffolds that can be used for soft tissue repair within patients. The medical technology was first brought to Australia over 20 years ago by […]
July 8th 2016Find out more
Admedus shares rise on hospital infusion pump supply deal with Arcomed
Admedus said today it won a supply contract with the new Royal Adelaide Hospital for the installation of the Arcomed chroma infusion pump systems. The supply tender includes ongoing technical and clinical support as well as consumable products for the systems over the next 5 years.
May 25th 2016Find out more
Admedus Wins 2016 Australian Manufacturer of the Year Award
After triumphing in the Most Innovative category, Admedus also took out the night’s biggest award ‘Manufacturer of the Year’. In August 2014 Admedus opened its state-of-the-art bio-manufacturing facility in Malaga, WA, and has experienced huge success in exporting its bio-scaffold regenerative medicine product, CardioCel, since then.
May 14th 2016Find out more
Admedus is a global healthcare company that develops, commercialises and distributes next generation medical technologies and devices. Our mission is to provide patients around the world with a better quality of life through access to our leading medical solutions and products.Learn More